Indications - Canagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Dosage & Administration - The recommended starting dose of Canaglif™ is 100 mg once daily and is taken before the first meal of the day. Dose can be increased upto 300 mg once daily in patients tolerating Canaglif™ 100 mg once daily who have an eGFR of 60 mL/min/1.73 m2 or greater and require additional glycemic control. If the eGFR of Patients is 45 to 60 mL/min/1.73 m2, the dose of Canaglif™ should be 100 mg once daily.
Side Effects - The most common adverse reactions of Canagliflozin are female genital mycotic infections, urinary tract infection and increased urination. Other side effects of Canagliflozin include low blood pressure, increases potassium blood levels (hyperkalemia), low blood glucose and increases Low-Density Lipoprotein (LDL-C).
Contraindications - History of serious hypersensitivity reaction to Canagliflozin, severe renal impairment, End Stage Renal Disease (ESRD), or on dialysis patients.
Others - Pregnancy & Lactation Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. For nursing mother discontinue drug or nursing.